CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title	Date of Registration	State
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial	17/10/2018	Registered
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM)	18/06/2021	Registered outdated
Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III.	2010-12-27	Registered
Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC)	30/04/2018	Registered
Dose scale-up and cohort expansion with the therapeutic mAb 14F7	04/12/2015	Registered outdated
EC122 HER-1 Prostate Phase I	15/11/2016	Registered
EGF vaccine- Advanced Lung tumors	2013-06-20	Registered
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors	2013-06-19	Registered
Evaluation of Safety and Efficacy of T1h (anti-CD6) as Monotherapy and in Combination with Methotrexate in Patientes with Rheumatoid Arthritis	2010-12-27	Registered
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II.	2010-12-28	Registered
h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin.	2010-12-29	Registered
Her1 vaccine in metastatic colon and prostate cancer	16/08/2023	Registered
hR3 in metastatic or recurrent colorectal cancer	22/11/2013	Registered
hR3 MaB and radiotherapy in highly malignant astrocytic tumors, phase III.	2010-12-28	Registered
hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma.	2010-12-29	Registered
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment.	2010-12-29	Registered
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders	18/06/2021	Registered outdated
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus	23/12/2016	Registered
Itolizumab for Moderate-to-Severe Psoriasis-phase 3	08/10/2015	Registered
Itolizumab for Relapsing Remitting Multiple Sclerosis	22/05/2015	Registered

Registered Trials

Registration process

CENTER OF MOLECULAR IMMUNOLOGY

About the RPCEC

Useful resources